Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Stock Overview
Explore Ascendis Pharma A/S’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
10.4B
P/E Ratio
-25.53
EPS (TTM)
$-6.66
ROE
1.91%
ASND Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ascendis Pharma A/S (ASND) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $184.73.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -25.53 and a market capitalization of 10.4B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Jan Moller Mikkelsen
1,017
Tuborg Boulevard 12, Hellerup
2015